JW Pharmaceutical Corp (001067) — Cash Flow-to-Debt Ratio
JW Pharmaceutical Corp (001067) has a Cash Flow-to-Debt Ratio of 0.18x as of September 2025, meaning its operating cash flow of ₩46.92 Billion could theoretically repay 0% of its total liabilities (₩257.46 Billion) in one year. See how financially flexible is JW Pharmaceutical Corp to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
JW Pharmaceutical Corp Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for JW Pharmaceutical Corp across 11 annual periods. For the full cash flow conversion analysis, see JW Pharmaceutical Corp (001067) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for JW Pharmaceutical Corp (2014–2024)
Year-by-year debt coverage analysis for JW Pharmaceutical Corp. Check 001067 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.29x | ₩79.39 Billion | ₩275.11 Billion | ▲ +25.7% |
| 2023 | 0.23x | ₩87.16 Billion | ₩379.60 Billion | ▲ +62.7% |
| 2022 | 0.14x | ₩56.76 Billion | ₩402.21 Billion | ▲ +246.1% |
| 2021 | 0.04x | ₩18.12 Billion | ₩444.51 Billion | ▼ -77.9% |
| 2020 | 0.18x | ₩63.05 Billion | ₩341.62 Billion | ▲ +14.0% |
| 2019 | 0.16x | ₩55.53 Billion | ₩343.12 Billion | ▲ +3.6% |
| 2018 | 0.16x | ₩52.11 Billion | ₩333.68 Billion | ▲ +68.1% |
| 2017 | 0.09x | ₩33.45 Billion | ₩360.10 Billion | ▲ +416.6% |
| 2016 | 0.02x | ₩6.74 Billion | ₩374.76 Billion | ▲ +267.1% |
| 2015 | -0.01x | ₩-4.17 Billion | ₩388.07 Billion | ▼ -154.6% |
| 2014 | 0.02x | ₩7.28 Billion | ₩369.22 Billion | — |